Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2024-04-09 Earnings Release
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux – Information financière du 1er trimestre 2024
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Information financière du 1er trimestre 2024" (bioMérieux – First Quarter 2024 Financial Information). It provides detailed financial figures (revenue, growth rates, segment breakdown) for the first quarter ending March 31, 2024. This content structure—a comprehensive report on a period shorter than a year, including detailed tables and management commentary on performance—is characteristic of an Interim/Quarterly Report. It is not merely an Earnings Release (ER) which typically contains only highlights, nor is it the full Annual Report (10-K). It is a detailed quarterly financial disclosure. Q1 2024
2024-04-09 French
Mars 2024 - Déclaration sur le nombre d'actions composant le capital social et le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share structure and voting rights, is not explicitly covered by the primary definitions (like 10-K, ER, IR). However, it relates to ownership structure and capital changes. The closest fit among the provided codes is not immediately obvious, but it is a mandatory regulatory disclosure concerning share capital/voting rights. Given the options, it is a specific regulatory filing concerning share structure. Since there is no specific code for 'Monthly Voting Rights Disclosure', I must evaluate the closest fit. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue (SHA). It is a mandatory regulatory filing. In the absence of a specific code for French voting rights disclosure, 'Regulatory Filings' (RNS) serves as the best general regulatory fallback, although it is a very specific type of filing. Upon re-evaluation of the definitions, none perfectly match this specific French regulatory requirement for monthly voting rights disclosure. Since it is a mandatory regulatory filing that doesn't fit the other specific categories (like dividend, management change, or earnings), RNS (Regulatory Filings) is the most appropriate fallback.
2024-04-05 French
bioMérieux and Mérieux NutriSciences partner with key food industry players to launch a new collaborative data-driven model
Regulatory Filings Classification · 95% confidence The document is a press release dated April 5th, 2024, announcing a partnership between bioMérieux and Mérieux NutriSciences to launch a new data-driven model for enhancing consumer safety control systems in the food industry. It details the initiative, mentions early partners (Barry Callebaut, Danone, Mars, etc.), includes executive quotes, and provides 'About' sections for both companies and contact information. This format is characteristic of a general corporate announcement or press release, which does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder materials (DEF 14A, AGM-R), or specific regulatory filings. Since it is a general corporate announcement that doesn't fit the highly specific categories like Capital Change (CAP), Dividend (DIV), or Director Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous corporate announcements not covered elsewhere.
2024-04-05 English
bioMérieux et Mérieux NutriSciences s'associent à des acteurs clés de l'industrie agroalimentaire pour lancer un nouveau modèle de collaboration, basé sur les données
Regulatory Filings Classification · 100% confidence The document is a press release dated April 5, 2024, announcing a new collaboration initiative called 'Trusted Third Party' between bioMérieux and Mérieux NutriSciences, involving major food industry players. It details the purpose, structure, and benefits of this new data-based model for improving food safety systems. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about a new business/industry development, which fits best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate announcement, or potentially Investor Presentation (IP) if it were structured as a deck, but given the press release format announcing a new partnership and initiative, RNS serves as the most appropriate general category for non-standard corporate news that isn't explicitly covered by other codes (like M&A, Director Dealing, or Capital Change). Since it is a detailed announcement of a new industry model rather than a brief notice of a report publication, RNS is chosen over RPA.
2024-04-05 French
Release of the Universal Registration Document including the Annual Financial report as of December 31, 2023
Report Publication Announcement Classification · 98% confidence The document text is very short (778 characters) and explicitly states that the '2023 Universal Registration Document including the Annual Financial Report' was filed and is now available on the company's website. This structure—announcing the publication of a major report rather than containing the full report content itself—fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K or AR, but the notice about them being released.
2024-03-28 English
Communiqué de mise à disposition du Document d'Enregistrement Universel incluant le rapport financier annuel au 31 décembre 2023
Report Publication Announcement Classification · 99% confidence The document is extremely short (837 characters) and its title explicitly states it is a 'Communiqué de mise à disposition du Document d'enregistrement universel 2023 incluant le rapport financier annuel' (Announcement of the availability of the 2023 Universal Registration Document including the annual financial report). It informs the reader that the main document has been filed with the AMF and is available on the company website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is available or published should be classified as a Report Publication Announcement (RPA).
2024-03-28 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.